BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3525176)

  • 1. Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.
    Janka-Schaub GE; Winkler K; Jürgens H; Goebel U; Gutjahr P; Spaar HJ
    Eur J Pediatr; 1986 Apr; 145(1-2):14-7. PubMed ID: 3525176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
    Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
    Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
    Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acute lymphoblastic leukemia in children. Long survivals obtained with protocols C2-72 and D-74 (1972-1977)].
    Ortega JJ; Javier G; Montagut JM; Torán N
    An Esp Pediatr; 1986 Feb; 24(2):87-97. PubMed ID: 3516041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
    Bleyer WA; Sather HN; Nickerson HJ; Coccia PF; Finklestein JZ; Miller DR; Littman PS; Lukens JN; Siegel SE; Hammond GD
    J Clin Oncol; 1991 Jun; 9(6):1012-21. PubMed ID: 2033414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood.
    Chessells JM; Durrant J; Hardy RM; Richards S
    J Clin Oncol; 1986 Dec; 4(12):1758-64. PubMed ID: 3537216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate dose methotrexate (IDM) in children with acute lymphocytic leukemia (ALL). An update.
    Freeman AI
    Sangre (Barc); 1985; 30(6):1007-33. PubMed ID: 3913034
    [No Abstract]   [Full Text] [Related]  

  • 9. [The Munich study on the treatment of acute lymphoblastic leukemia in childhood (ALL 77-02)].
    Graubner UB; Haas RJ; Janka G; Gaedicke G; Kohne E; Rieber EP
    Klin Padiatr; 1985; 197(3):207-14. PubMed ID: 3892149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of acute lymphocytic leukemia in childhood with intermediate dose methotrexate and CNS irradiation. A report of the ALL 77-02 study group.
    Haas RJ; Janka G; Gaedicke G; Kohne E; Netzel B
    Blut; 1983 Dec; 47(6):321-31. PubMed ID: 6580929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group].
    Rinsho Ketsueki; 1989 Jul; 30(7):967-74. PubMed ID: 2681882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
    Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
    Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from childrens cancer study group.
    Miller DR; Leikin S; Albo V; Sather H; Karon M; Hammond D
    Cancer; 1983 Mar; 51(6):1041-9. PubMed ID: 6336986
    [No Abstract]   [Full Text] [Related]  

  • 15. Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.
    Schaison G; Leverger G; Bancillon A; Marty M; Olive D; Cornu G; Griscelli C; Lemerle S; Harousseau JL; Bonnet M
    Haematol Blood Transfus; 1987; 30():461-5. PubMed ID: 3305213
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute lymphoblastic leukemia in childhood: the COALL studies].
    Janka GE; Winkler K; Jürgens H; Göbel U; Gutjahr P; Spaar HJ
    Klin Padiatr; 1986; 198(3):171-7. PubMed ID: 3523023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute lymphoblastic leukemia of high risk: results of a therapeutic protocol].
    Castel V; Verdeguer A; Ferris J; Esquembre C
    An Esp Pediatr; 1987 Nov; 27(5):331-4. PubMed ID: 3481522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.